MedTrace Logo

A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis

NCT02598440 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 341

Last updated 2016-11-02

No results posted yet for this study

Summary

This study will evaluate participant-reported preference for either ibandronate or a comparator drug in women with postmenopausal osteoporosis. The anticipated time of study treatment is 6 months, and the target sample size is 338 individuals.

Conditions

  • Postmenopausal Osteoporosis

Interventions

DRUG

Alendronate

Participants wil receive once-weekly oral alendronate (70 mg tablet)

DRUG

Ibandronate

Participants wil receive once-monthly oral ibandronate (150 mg tablet)

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-03-31
Primary Completion
2005-05-31
Completion
2005-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02598440 on ClinicalTrials.gov